Benzinga··Vandana SinghBiogen Stock Slides on Alzheimer's Drug Setback Despite Acquisition Boost
$BIOGEN fell 4.97% after Alzheimer's drug diranersen missed primary endpoint, though showed cognitive benefits. Company completed Apellis acquisition adding $689M annual revenue.
APLSBIIBIONSphase 2 trialAlzheimer's disease